NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC cut its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 76.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,280 shares of the medical research company's stock after selling 54,330 shares during the period. Schonfeld Strategic Advisors LLC's holdings in NeoGenomics were worth $268,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of NEO. Loomis Sayles & Co. L P increased its holdings in shares of NeoGenomics by 48.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company's stock valued at $29,528,000 after acquiring an additional 584,502 shares during the period. Norges Bank acquired a new stake in NeoGenomics during the 4th quarter worth $6,273,000. Jennison Associates LLC grew its position in NeoGenomics by 18.7% during the 4th quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock worth $24,963,000 after purchasing an additional 238,288 shares during the last quarter. Greenhouse Funds LLLP increased its stake in NeoGenomics by 5.3% in the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock valued at $77,487,000 after purchasing an additional 237,491 shares during the period. Finally, Segall Bryant & Hamill LLC raised its holdings in shares of NeoGenomics by 11.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock valued at $34,836,000 after buying an additional 220,415 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

Insiders Place Their Bets

In other news, COO Warren Stone bought 5,700 shares of NeoGenomics stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $8.58 per share, for a total transaction of $48,906.00. Following the acquisition, the chief operating officer now owns 108,280 shares in the company, valued at approximately $929,042.40. This trade represents a 5.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Jeffrey Scott Sherman purchased 20,000 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were purchased at an average cost of $7.51 per share, for a total transaction of $150,200.00. Following the completion of the purchase, the chief financial officer now directly owns 158,494 shares in the company, valued at $1,190,289.94. The trade was a 14.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 65,600 shares of company stock worth $512,438. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NEO. Needham & Company LLC lowered their price target on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Morgan Stanley lowered their target price on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. The Goldman Sachs Group cut their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. StockNews.com raised NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday. Finally, Leerink Partners downgraded NeoGenomics from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $25.00 to $9.00 in a research note on Wednesday, April 30th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, NeoGenomics currently has a consensus rating of "Hold" and a consensus price target of $13.83.

NeoGenomics Price Performance

Shares of NEO traded up $0.27 on Friday, reaching $8.11. The stock had a trading volume of 1,257,184 shares, compared to its average volume of 1,123,625. NeoGenomics, Inc. has a twelve month low of $6.08 and a twelve month high of $19.12. The firm has a market capitalization of $1.04 billion, a PE ratio of -13.08 and a beta of 1.60. The firm has a 50-day moving average of $9.07 and a 200 day moving average of $12.94. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. During the same period last year, the firm earned ($0.02) EPS. The company's quarterly revenue was up 7.6% compared to the same quarter last year. Sell-side analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.